Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade and Melphalan Conditioning for Tandem PBSCT in Refractory Multiple Myeloma
NCT00307086Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2005
- Primary completion
- Mar 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM) and plasma cell leukemia (PCL), sponsored by Moffitt Cancer Center. Primary endpoints: Maximum Tolerated Dose of Bortezomib, Safety and Tolerability and 2 more. Started Jun 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT00307086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307086.